Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Online Menopause Information–Seeking Search Patterns and Commercial Content Over 2 Decades
Farina, Francesca R., Griffith, James W., Faubion, Stephanie S., Hickey, Martha, Lensen, Sarah, Christmas, Monica, Farina, Francesca R , Faubion, Stephanie S. , Hickey, Martha , Lensen, Sarah F. , Christmas, Monica

Mayo Clinic

JAMA Network Open | June 4, 2026 | Volume: 9 | Issue: 6 | Pages: e2616596

10.1001/jamanetworkopen.2026.16596 | PMID 42241006 Get It

This cohort study evaluates 20-year trends to quantify changes in menopause-related online searches compared with other health domains.
A Structured Consent Framework for Research of Electroconvulsive Therapy in Advanced Dementia
Holzman, Andrew L., Forester, Brent P. , Sanghani, Sohag , Hermida, Adriana P., Petrides, Georgios, Nykamp, Louis, Kung, Simon , Williams, Sarah , Pagali, Sandeep R. , Lapid, Maria I. , Holzman, Andrew E. , Wilkins, James M. , Hermida, Adriana P., Mueller, Martina , Patrick, Regan , Gentry, Melanie T

Mayo Clinic

The Journal of ECT | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/yct.0000000000001296 | PMID 42240217 Get It

Objectives: The electroconvulsive therapy for the acute management of severe agitation in dementia (ECT-AD) trial is a multisite study evaluating the effectiveness of ECT for severe agitation in individuals with advanced dementia. Given that participants lack decisional capacity because of advanced cognitive impairment, the trial required a structured and ethically sound approach to obtaining informed consent and assent across jurisdictions with differing legal requirements, including Massachusetts, New York, Georgia, Minnesota, and Michigan. This paper describes the approach used in the study. Methods: We describe the consent framework developed for the ECT-AD trial, including procedures for identifying legally authorized representatives, complying with state-specific laws for ECT consent, obtaining surrogate consent for research participation, and assessing patient assent and dissent using a standardized tool. Conclusions: The approach used in this study may serve as a practical model for future research involving individuals without decision-making capacity and legally complex interventions such as ECT.
Stool Microbiota, Metabolites, and Fecal Incontinence in Women
Arya, Lily A. , Kashyap, Purna , Carnes, Megan U., Mathur, Ravi, Richter, Holly E., Andy, U., Jelovsek, J. Eric, Siddiqui, Nazema Y., Morrow, Casey D. , Lefkowitz, Elliot J. , Pol, William J. Van Der, Broeckling, Corey, Carper, Benjamin, Jeney, Sarah E.S., Zyczynski, Halina M. , Dyer, Keisha Y., Carberry, Cassandra, Mazloomdoost, D., Network, for the NICHD Pelvic Floor Disorders, Arya, Lily A. , Carnes, Megan Ulmer , Mathur, Ravi , Richter, Holly E , Andy, Uduak Umoh , Pol, William J. Van Der, Broeckling, Corey D. , Carper, Benjamin , Jeney, Sarah E.S. , Carberry, Cassandra, Mazloomdoost, Donna , Gantz, Marie G.

Mayo Clinic

Urogynecology | June 4, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/spv.0000000000001885 | PMID 42240124 Get It

Importance Stool metabolites influencing gut motility and sensation may contribute to fecal incontinence (FI). Objective The objective of this study was to test whether FI is associated with higher levels of butyrate and Clostridiales taxa in stool. Study Design Stool metabolites and microbiota were compared between 96 women with FI and 42 controls. FI frequency and subtype (urgency vs insensible) were measured using a 14-day bowel diary, St. Mark’s score, and the Accidental Bowel Leakage questionnaire. Metabolite analysis included targeted analysis (8 short-chain fatty acids including butyrate, 17 bile acids, and 8 tryptophan derivatives) and untargeted analysis. Stool microbiota were characterized using 16S rRNA gene sequencing. Multivariable and exploratory multiomics factor analysis were performed with statistical significance defined as false discovery rate (FDR) ≤0.10. Results The FI group had a higher proportion of Bristol stool types 2 and 6 than controls ( P = 0.005). The mean number of leaks for the FI group was 1.7 ± 1.7 per day, 38% had urgency FI, and 39% had insensible FI. There was no significant difference between groups in butyrate levels and Clostridiales taxa. Multiomics analysis identified glycerolipids (monoacylglycerols and diacylglycerols) associated with FI (FDR = 0.08). In addition, insensible FI was associated with glycerolipids, long-chain saturated and monounsaturated fatty acids, phospholipids, and dipeptides (FDR = 0.08–0.09). The top weighted microbiota associated with these metabolites were Lachnospiraceae and Ruminococcaceae; however, these taxa were not directly associated with FI. Conclusion Butyrate and Clostridiales were not associated with FI. Novel stool metabolite signatures were identified, suggesting new biological pathways and potential therapeutic targets for FI.
SDAMPP report #1: Holistic review for medical physics residency applicant selection
Yu, Amy S. , Besemer, Abby, Buckey, Courtney, Cetnar, Ashley, DeWeese, Lindsay, Gao, Yu, Lindsay, Patricia, Rodrigues, Anna, Schubert, Leah, Wilson, Joshua, Wisnoskie, Sarah, Yu, Amy Shu-Jung , Buckey, C, Cetnar, Ashley J. , DeWeese, Lindsay , Lindsay, Patricia E, Schubert, Leah , Wisnoskie, Sarah, Juang, Titania

Mayo Clinic

Journal of Applied Clinical Medical Physics | June 4, 2026 | Volume: 27 | Issue: 6 | Pages: No page available

10.1002/acm2.70649 | PMID 42240068 Get It

Abstract Clinical medical physics is a profession that intersects with various groups as part of a broader healthcare team, including dosimetrists, radiation therapists, radiologic and MRI technologists, IT specialists, and physicians. Success in this field requires academic and technical excellence as well as comprehensive skills for working effectively within an interdisciplinary healthcare team. When hiring medical physics residents, the selection of well‐rounded and highly qualified candidates can be facilitated through a holistic review process that ensures consideration of traditional metrics such as academic performance while also accounting for the importance of various experiences, personal attributes, and intrinsic motivations that impact clinical performance and patient care. The Association of American Medical Colleges (AAMC) emphasizes an overall consideration of Experiences, Attributes, Competencies, and Metrics (EACM) as important for the search process. As part of the healthcare community, medical physics shares the same commitment to high‐quality patient care. By adopting the AAMC's EACM framework, medical physics residency programs can strengthen the fairness, rigor, and overall effectiveness of their application review processes—ultimately benefiting applicants, the medical physics community, and the patients we serve. This Society of Directors of Academic Medical Physics Programs (SDAMPP) task report aims to provide information and resources for applying holistic review to the applicant selection process for medical physics residency programs. Our objective is to enable program directors to reevaluate their selection methods in the context of institutional and program missions and goals and to improve the quality and specificity of recruitment by integrating holistic review concepts into their residency recruitment processes. This initiative can inspire change in recruitment practices, aid programs in hiring well‐rounded and well‐qualified residents, and support the professional growth of our trainees in healthcare. This report provides an overview of holistic reviews and its core principles. We review the current literature and provide evidence from successful implementations of holistic review in other medical fields to illustrate how it can benefit our field. Furthermore, we outline actionable recommendations to facilitate transitioning to a holistic review framework and address potential barriers with practical solutions. A supplemental workbook is provided to guide residency programs in developing their own holistic application review and interview processes. With this report, we aim to provide practical implementation guidelines that will allow residency program directors to implement a selection methodology that comprehensively assesses the full qualifications of individual candidates and ultimately fosters the development of versatile and competent clinical medical physicists who are best equipped to advance the field, meet patient needs, and improve patient care.
frontMIND: Phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
Lenz, Georg, Trněný, Marek, Burke, John M., Nowakowski, Grzegorz S., Düll, Johannes, Jeon, Youngwoo , Cheah, Chan, Westin, Jason, Ye, Joseph Z., Caguioa, Priscilla B. , Belada, David, Shin, Ho Jin, Amorim, Sandy, Colucci, Philomena, Ioannidis, Sonia, Lenz, Georg , Trněný, Marek , Burke, John M. , Nowakowski, Grzegorz S. , Fox, Christopher P. , Chiappella, Annalisa , Westin, Jason R. , Belada, David , Oh, Sung Yong , Colucci, Philomena M., Cheng, Lulu L , Vitolo, Umberto

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba7000 Get It

LBA7000 Background: ~40% of DLBCL pts are not cured with first-line (1L) R-CHOP, underscoring a significant unmet need for more effective 1L regimens. Tafa (anti-CD19 mAb) + Len-R-CHOP in the phase 1b First-MIND study demonstrated safety and efficacy in pts with newly diagnosed disease. frontMIND, a phase 3, double-blind, placebo-controlled study, compared Tafa-Len-R-CHOP vs R-CHOP in pts with high-risk aggressive BCLs. Methods: Pts aged 18–80 y with newly diagnosed, high-intermediate/high-risk DLBCL or HGBL (IPI 3–5, aaIPI 2–3 if ≤60 y) and ECOG PS 0–2 were randomized 1:1 to Tafa-Len-R-CHOP or R-CHOP. Primary endpoint was investigator-assessed PFS; secondary endpoints included: EFS, OS, CR, ORR, safety. Results: At primary analysis (data cutoff Oct 20, 2025), 899 pts were randomized to Tafa-Len-R-CHOP (n=448) or R-CHOP (n=451); baseline characteristics were similar between arms. With a median follow-up of 35.2 mo, Tafa-Len-R-CHOP achieved a statistically significant improvement in PFS vs R-CHOP (HR 0.75 [95% CI: 0.59, 0.96]; P =0.019) in the overall population; in pts with centrally confirmed lymphoma subtypes (n=773), PFS HR was 0.68 (95% CI: 0.52, 0.88) and 24-mo PFS was 72.7% vs 62.2%. PFS benefit was observed with Tafa-Len-R-CHOP in both molecular COO subtypes, ABC and GCB (data will be presented). Tafa-Len-R-CHOP significantly improved EFS vs R-CHOP; CR and ORR were similar between arms and HR for OS was 0.85 (final OS planned at 5y) (Table). Any-grade TEAEs were similar in treatment arms (98.6% vs 97.1%); more grade ≥3 TEAEs occurred with Tafa-Len-R-CHOP vs R-CHOP (86.7% vs 76.1%). Discontinuations due to TEAEs occurred in 25.7% vs 17.9% and deaths due to TEAEs in 5.9% vs 3.8% of pts for Tafa-Len-R-CHOP vs R-CHOP. Overall, there were fewer deaths with Tafa-Len-R-CHOP vs R-CHOP (18.5% vs 21.7%). Conclusions: The primary endpoint of frontMIND was met; Tafa-Len-R-CHOP resulted in a significant 25% reduction in risk of disease progression or death compared with R-CHOP, with an 8.2% difference in 24-month PFS rate in the overall population and 10.5% difference in pts with centrally confirmed lymphoma subtypes. TEAEs were manageable and consistent with the expected safety profile. Tafa-Len-R-CHOP represents a potential new 1L standard of care for pts with both COO subtypes of high-risk DLBCL or HGBL. Clinical trial information: NCT04824092 . Efficacy outcomes by treatment arm.* Variable Tafa-Len-R-CHOP(n=448) R-CHOP(n=451) HR or OR(95% CI) P value PFS, # events (%) † 121 (27.0) 155 (34.4) 0.75 (0.59, 0.96) 0.019 PFS rate at 24 mo, % 71.1 62.9 − − PFS rate at 36 mo, % 67.3 60.7 − − EFS, # events (%) 154 (34.4) 191 (42.4) 0.79 (0.64, 0.97) 0.026 OS, # events (%) 82 (18.3) 95 (21.1) 0.85 (0.63, 1.14) 0.270 CR at EOT, n (%) 292 (65.2) 294 (65.2) 0.998 (0.76, 1.31) 0.987 ‡ ORR at EOT, n (%) 360 (80.4) 343 (76.1) 1.290 (0.94, 1.78) 0.120 ‡ *Investigator-assessed. † Progressive disease or death from any cause. ‡ Nominal P value.
Mast cell score associates with wide-spread mast cell symptoms and comorbidities in patients with hEDS and HSD
Wilson, Frances C., Zangerle, Derek J. , Rozen, Lincoln E. , Fliess, Jessica J. , Darakjian, Ashley A. , Sacco, Keith , Hamilton, Charwan , Strandes, Max W , Puls, Alayna M , Hartmoyer, Cameron J. , Reyes, Sophia N. Witola , Menton, Stacey M. , Dudenkov, Daniel V. , Gonzalez-Estrada, A, Solomon, Sarah C., Stephens, Ina, Wang, Benjamin W.E., Botella, R, Zeman, Ashley M., Gajarawala, Shilpa , Wilson, Frances C , Sacco, Keith A , Witola Reyes, Sophia N , Gonzalez-Estrada, Alexei , Atwal, Paldeep S , Shufelt, Chrisandra L , Zeman, Ashley M , Knight, Dacre R T , Gajarawala, Shilpa , Bruno, Katelyn A , Fairweather, DeLisa , Gonzalez‐Estrada, Alexei , Solomon, Sarah Cohen, Shufelt, Chrisandra , Bruno, Katelyn A. , Fairweather, DeLisa

Mayo Clinic

No container title available | June 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.31.26354552 | PMID 42282176 Get It

Abstract Background Wide-spread mast cell (MC)-associated symptoms and MC activation syndrome (MCAS) are often reported in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). The goal of this study was to develop a novel MC score based on 11 self-reported MC-related conditions with clinical and research utility to better understand MC symptoms in hEDS and HSD patients. Methods From November 1, 2019, to June 13, 2025, patients ( n =2,141) filled out an Intake Questionnaire at the Mayo Clinic Florida EDS Clinic that included 11 self-reported questions related to categories of MC-related conditions for a MC score ranging from 0/11 to 11/11. Based on the MC score distribution in hEDS and HSD patients, a MC score of 0-1 was considered a low MC score and ≥5 was considered a high MC score. Symptoms/comorbidities were compared between patients with high vs. low MC scores. Results From the 2,141 hEDS/HSD patients, 535 (25.0%) had a MC score ≥5 (Hi MC). MCAS-specific symptoms such as nausea and vomiting were reported more often in hEDS/HSD patients with a high vs. low MC score ( p <0.0001). Random clinical blood tryptase and urinary MC markers were not elevated in patients with high MC scores ( n =50/group), although high MC scores were found to significantly reduce urinary creatinine levels indicating that the protein used to normalize data was affected by MC activity. In contrast, random blood IgE, tryptase and major basic protein (MBP) by ELISA were increased in patients with high MC scores (e.g., IgE hEDS p =0.0004, HSD p =0.003). Of note, the percentage of patients reporting abuse or post-traumatic stress disorder was nearly doubled in patients with high vs. low MC scores (Abuse and PTSD: hEDS p < 0.0001; HSD p < 0.0001). Overall, 109/135 (80.7%) in hEDS and 129/135 (95.6%) in HSD reported more symptoms/comorbidities if they had a high MC score. Conclusions We found that hEDS/HSD patients with high MC scores self-reported more widespread symptoms/comorbidities and higher MC-related blood markers than patients with low MC scores indicating the utility of this tool to evaluate the level of widespread MC activity in hEDS, HSD and other patients.
Pediatric epilepsy surgery: Global survey of referral and presurgical evaluation practices
Ramantani, Georgia , Cross, J. Helen , Cserpán, Dorottya , Ahemad, Emtnan , Aparicio, Javier , Arzimanoglou, Alexis , Barba, Carmen , Bingaman, William , Braun, Kees , Burman, R J, Cai, Lixin , Cao, Dezhi , Caraballo, Roberto , Cloppenborg, Thomas , Cukiert, Cristine Mella , Dal, Sameer , Englot, Dario, Enright, Noelle , Sorbets, Sarah Ferrand , Mahecha, Laura Guio, Hallböök, T , Harvey, A. Simon, Holthausen, H, Jiang, Y , Kannan, Lakshminarayanan , Lallas, Matt, Valappil, Ahsan Moosa Naduvil , Patil, Sandeep Bhagwan , Pieper, Tom , Tripathi, Manjari , Vendégh, Lejla, Weiner, Howard , Wilmshurst, Jo, Smith, MK, Group, ILAE Pediatric Epilepsy Surgery Task Force and Study, Wilmshurst, Jo M. , Burman, Richard J. , Shetty, Jay , Burman, Richard J , Butler, James , Cai, Li-Xin , Cao, Dezhi , Caraballo, Roberto H , Chipaux-Raffo, Mathilde , Cloppenborg, Thomas , Cukiert, Arthur , Dal, Sameer , Englot, Dario J , Enright, Noelle , Fallah, Aria , Ferrand Sorbets, Sarah , Feucht, Martha , Gill, Deepak , Hadjinicolaou, Aristides , Harvey, A Simon , Holthausen, Hans , Jiang, Yuwu , Kannan, Lakshminarayanan , Katlowitz, Kalman A , Kotulska-Jóźwiak, Katarzyna , Kudr, Martin , Lallas, Matt , Patil, Sandeep Bhagwan , Specchio, Nicola , Tripathi, Manjari , Wilmshurst, Jo M , Smith, Mary Lou , Wirrell, Elaine C , Ramantani, Georgia , Cross, Helen J , Shetty, Jay , Barba, Carmen , Braun, Kees P. J. , Englot, Dario J. , Fallah, Aria , Feucht, Martha , Moosa, Ahsan N. , Specchio, Nicola , Wirrell, Elaine

Mayo Clinic

Epilepsia | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70312 | PMID 42227967 Get It

Abstract Objective Pediatric epilepsy surgery is well established, but contemporary global data on referral and presurgical evaluation practices are lacking. This International League Against Epilepsy (ILAE) Pediatric Epilepsy Surgery Task Force study provides an updated overview of current trends and regional differences. Methods Group‐level data were collected from 61 epilepsy surgery programs (49 pediatric‐only) across 29 countries and six continents, identified through ILAE networks, and included all children and adolescents treated in 2023 who underwent presurgical evaluation/epilepsy surgery. Results Group‐level data were available for 2427 patients. Mean age at surgery was 9.1 ± 4.9 years; mean epilepsy duration was 5.3. At surgery, 3.2% were <1 year old (highest in Oceania: 5.1%), and 6.1% were nonpharmacoresistant (highest in Europe: 15.0%). Prior neurosurgery was reported in 14.2% (highest in North America: 28.8%), including 8.0% resections (6.1% for epilepsy, 1.5% for tumors; highest in Oceania: 16.5%), 2.3% disconnections (1.3% corpus callosotomy; highest in South America: 4.7%), and 4.2% neuromodulation (3.7% vagal nerve stimulation, .2% responsive neurostimulation, one deep brain stimulation; highest in North America: 12.2%). Developmental and epileptic encephalopathies (DEEs) at surgery included Lennox–Gastaut syndrome (7.4%), infantile epileptic spasms syndrome (5.1%), and DEE with spike–wave activation in sleep (1.5%). Presurgical investigations included fluorodeoxyglucose positron emission tomography (52.6%; highest in Oceania: 79.7%), genetic testing (46.8%; highest in Asia: 54.3%), magnetic resonance imaging (MRI) postprocessing (32.4%; highest in South America: 53.0%), functional MRI (fMRI; 15.2%; highest in North America: 40.3%), magnetoencephalography (11.9%; highest in North America: 39.3%), single photon emission computed tomography (9.6%; highest in North America: 22.2%), high‐density electroencephalography (EEG; 1.9%; highest in Europe: 4.7%), source localization (1.6%; highest in Oceania: 7.6%), Wada test (1.2%; highest in North America: 3.5%), and EEG‐fMRI (.5%; highest in Europe: 1.1%). Significance Despite some early surgeries, including in infancy and before pharmacoresistance, mean epilepsy duration before surgery remains >5 years. Reoperations are common, with resection more frequent than neuromodulation. Genetic testing in nearly half of patients reflects its growing relevance, and the high rate of DEEs underscores the complexity of surgical candidates.
Continuous vs. Interrupted Multi-Talker Babble Background Noise: Impact on Speech Perception in Bimodal Cochlear Implants
Kolberg, Courtney, Holbert, Sarah O., Graham, Madison K., DeJong, Melissa D., Hogan, Cynthia A. , Saoji, Aniket A. , Hogan, Cynthia H , Kolberg, Courtney

Mayo Clinic

Journal of Clinical Medicine | June 1, 2026 | Volume: 15 | Issue: 11 | Pages: 4232

10.3390/jcm15114232 | PMID 42279093 Get It

Background/Objectives: Speech perception is measured in quiet and in the presence of background noise, such as multi-talker babble (MTB), to establish cochlear implant (CI) candidacy and measure post-operative outcomes. Testing protocols often use interrupted noise that begins just before and ends shortly after the target sentence, providing insufficient time for the noise-reduction algorithms to activate in the hearing device and provide an improved signal-to-noise ratio (SNR). Furthermore, interrupted noise does not allow the hearing-impaired user to acclimatize to the abrupt onset of noise or to focus on the target sentence, a challenge related to auditory stream segregation. The present study compares speech perception in bimodal CI users across interrupted and continuous MTB noise conditions to highlight performance differences between these two distinct listening environments. Methods: Speech perception was evaluated for two different bimodal CI groups. Group 1: This group evaluated an automatic hearing aid program across three environments: quiet, continuous MTB, and interrupted MTB. Group 2: This group evaluated two manual hearing aid programs across the same three environments (quiet, continuous, and interrupted MTB). Results: For Group 1, scores in quiet reached 88%, significantly declined in interrupted MTB (38%), but improved in continuous MTB (67%). For Group 2, no significant mean differences were found between interrupted and continuous noise across the two manual programs, though individual variations persisted. Conclusions: Based on the findings of this study, continuous noise rather than interrupted noise should be utilized for establishing CI candidacy and evaluating post-implantation speech perception.
Current views on sustainability in urology: findings from the North Central Section of American Urological Association membership survey
Shi, Chloe, Wang, Susanna, Steinberg, Ryan, DeLancy, John O., Goh, Keow, Adelstein, Sarah, Dangle, Pankaj, Lin, Frank C., Miller, AR, Gettman, Matthew, Steinberg, Ryan L. , Miller, Adam , Adelstein, Sarah A. , Dangle, Pankaj , Lin, Frank C.

Mayo Clinic

Frontiers in Urology | June 1, 2026 | Volume: 6 | Issue: No issue available | Pages: No page available

10.3389/fruro.2026.1818561 | PMID 42305906 Get It

Objective The United Nations defines sustainability as meeting needs of the present without compromising future generations. While often equated to “saving the planet”, sustainability is a diverse topic. Healthcare generates &gt;5% of CO 2 emissions worldwide, yet sustainability efforts in urology are limited. The North Central Section of the American Urological Association (NCSAUA) recently convened a Sustainability Task Force to address this topic. This study queried members on sustainability in urologic practice. Methods Following literature review on sustainability in surgery/urology, a 19-item anonymous REDCap survey was developed and distributed via email to NCSAUA members (N = 1607). The survey assessed current best practice, institutional/personal sustainability, and demographics. Responses were compiled and summarized using descriptive statistics. Results Survey response rate was 4.9% (79/1607). Respondents were most commonly from metropolitan areas (82%), male (71%), and in practice for 5–14 years (29%). Sustainability topics were prioritized as: (1) financial, (2) future workforce, (3) environmental. Over half (56%) reported no institutional sustainability programs or were unaware of them. Instrument (67%), computer (68%), and paper (65%) recycling were supported by a majority of respondents. However, only 28% and 29% of respondents reported current institutional use of instrument and computer recycling, respectively. Telemedicine was infrequent, with most urologists (58%) conducting 0-5% of visits virtually. Conclusions Current institutional and urologic practice emphasis on sustainability is low. Respondents ranked highest sustainability priorities as financial and future workforce. Efforts to address environmental sustainability were also supported, namely reduction of disposables and waste. The findings support the development of targeted programs to advance sustainability priorities widely.
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)
Tallantyre, Emma C , Planchon, Sarah M. , Howard, Harriet, Mays, John, Frowd, Nadia, Cohen, Jeffrey A. , Hersh, Carrie M. , Miller, Deborah , Dever, Meredith , Gray, Emma H., LaRocca, Nicholas G., Bale, Clare , Covey-Crump, Gwen, Alvarez, Enrique, Craner, Matt, Freeman, L, Frost, N, Hobart, JC, Hutton, George J, Hyland, Megan , Kalra, S, Kannan, Meena, Kantarci, OH , Lashley, Daniel, Lily, Oliver, Mahad, D, Nicholas, J, Nicholas, R, Paling, David, Pearson, Owen , Rice, Claire M , Samudralwar, Rohini, Schmalstieg, William F., Singh, M, The, E Zune, Zabeti, Aram , Love, Thomas E, Gunzler, Douglas , Liu, Y, GERRY, STEPHEN, Evangelou, N, Hersh, Carrie M , Miller, D M , Nakamura, Kunio , Goldman, Myla D , Harding, Katharine E , Hobart, Jeremy , Kalra, Seema , Nicholas, Richard , Pearson, Owen R , Rice, Claire M , Weinstock‐Guttman, Bianca , Evangelou, Nikos , Ontaneda, Daniel , Cohen, Jeffrey Allen , Tallantyre, Emma Clare , Coles, Alasdair J. , Covey-Crump, Gwen L , Arun, Tarunya , Brownlee, Wallace J , Craner, Matthew J., Freeman, Leorah A. , Goldman, Myla , Gupta, Rajesh , Hutton, George J., Kantarci, Orhun H. , Mahad, Don , Paling, David , The, Ei Zune , Love, Thomas E.

Mayo Clinic

Multiple Sclerosis Journal | May 31, 2026 | Volume: 32 | Issue: 7 | Pages: 722-736

10.1177/13524585261449988 | PMID 42218617 Get It

Background: There is growing support for high-efficacy disease-modifying therapy (DMT) in multiple sclerosis (MS), but escalation (ESC) approaches remain common. Objective: To describe decision-making in a pragmatic trial of early high-efficacy treatment (EHT) versus ESC. Methods: DELIVER-MS is a multi-center, pragmatic, randomized controlled trial (RCT) with a parallel observational study (OBS), which enrolled treatment-naïve people with RRMS in 31 UK/US sites. Primary outcome was as follows: 36-month brain volume loss according to initial treatment approach (EHT vs. ESC). Stepwise multivariable logistic regression was used to predict participation in RCT versus OBS and choice of EHT versus ESC within the OBS cohort. Results: In total, 816 people with MS were enrolled. Participants declined randomization due to preference for a particular DMT (85%), efficacy concerns (20%), and safety concerns (9%). RCT versus OBS participation was associated with lower relapse rate ( p = 0.043) and greater brain parenchymal fraction ( p = 0.002). Among 374 in the OBS cohort, 125 (33%) chose ESC and 249 (67%) chose EHT. People commencing EHT had higher education attainment ( p < 0.001) and relapse rate ( p = 0.025). Conclusion: Baseline DELIVER-MS data demonstrate that participants with milder disease are more likely to participate in RCT. The choice of EHT versus ESC was associated with demographic factors and disease activity. Clinical trial registration: NCT03535298